Dr. Philippe Ruszniewski on NETTER-1 Study Results
Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.
Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase III NETTER-1 study.
The study, which investigated the use of 177-Lu-Dotatate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (NETs), met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in progression-free survival for 177-Lu-Dotatate versus a double dose of octreotide (Sandostatin LAR).
There are not many options for patients with neuroendocrine tumors, so these results are exciting, says Ruszniewski.
<<<
